These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31586799)

  • 61. Serum Tumor Necrosis Factor-Alpha Levels Correlate with Cognitive Function Scales Scores in Multiple Sclerosis Patients.
    El-Salem K; Al-Mistarehi AH; Hanan Khalil ; Alham Al-Sharman ; Yassin A
    Mult Scler Relat Disord; 2021 Jan; 47():102621. PubMed ID: 33197871
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Cambridge Neuropsychological Test Automated Battery (CANTAB) Versus the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) for the Assessment of Cognitive Function in Patients with Multiple Sclerosis.
    Talebi M; Majdi A; Kamari F; Sadigh-Eteghad S
    Mult Scler Relat Disord; 2020 Aug; 43():102172. PubMed ID: 32442887
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.
    Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P
    Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS.
    Strober L; Englert J; Munschauer F; Weinstock-Guttman B; Rao S; Benedict RH
    Mult Scler; 2009 Sep; 15(9):1077-84. PubMed ID: 19556311
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessing the criterion validity of four highly abbreviated measures from the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).
    Gromisch ES; Zemon V; Holtzer R; Chiaravalloti ND; DeLuca J; Beier M; Farrell E; Snyder S; Schairer LC; Glukhovsky L; Botvinick J; Sloan J; Picone MA; Kim S; Foley FW
    Clin Neuropsychol; 2016 Oct; 30(7):1032-49. PubMed ID: 27279357
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Thalamus volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients.
    Rojas JI; Murphy G; Sanchez F; Patrucco L; Fernandez MC; Miguez J; Funes J; Golimstok A; Cristiano E
    Neuroradiol J; 2018 Aug; 31(4):350-355. PubMed ID: 29869576
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Depression and Fatigue in Patients With Multiple Sclerosis Have No Influence on the Parameters of Cognitive Evoked Potentials.
    Lazarevic S; Azanjac Arsic A; Aleksic D; Toncev G; Miletic-Drakulic S
    J Clin Neurophysiol; 2021 Jan; 38(1):36-42. PubMed ID: 31725033
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The weekly calendar planning activity in multiple sclerosis: A top-down assessment of executive functions.
    Goverover Y; Toglia J; DeLuca J
    Neuropsychol Rehabil; 2020 Aug; 30(7):1372-1387. PubMed ID: 30810484
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.
    Yam C; Merlo D; Stankovich J; Darby D; Gresle M; Kalincik T; Kilpatrick TJ; Lechner-Scott J; Taylor B; Barnett M; Butzkueven H; van der Walt A
    Mult Scler Relat Disord; 2020 Aug; 43():102212. PubMed ID: 32474286
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
    Moccia M; Lanzillo R; Costabile T; Russo C; Carotenuto A; Sasso G; Postiglione E; De Luca Picione C; Vastola M; Maniscalco GT; Palladino R; Brescia Morra V
    J Neurol; 2015; 262(4):961-7. PubMed ID: 25673130
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neuropsychological characteristics of benign multiple sclerosis patients: A two-year matched cohort study.
    Hegedüs K; Kárpáti J; Iljicsov A; Simó M
    Mult Scler Relat Disord; 2019 Oct; 35():150-155. PubMed ID: 31376686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Tillema JM; Hulst HE; Rocca MA; Vrenken H; Steenwijk MD; Damjanovic D; Enzinger C; Ropele S; Tedeschi G; Gallo A; Ciccarelli O; Rovira A; Montalban X; de Stefano N; Stromillo ML; Filippi M; Barkhof F;
    Mult Scler; 2016 Jun; 22(7):901-9. PubMed ID: 26432859
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis.
    Favaretto A; Lazzarotto A; Riccardi A; Pravato S; Margoni M; Causin F; Anglani MG; Seppi D; Poggiali D; Gallo P
    PLoS One; 2017; 12(10):e0185626. PubMed ID: 29045421
    [TBL] [Abstract][Full Text] [Related]  

  • 75. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increased thalamic intrinsic oscillation amplitude in relapsing-remitting multiple sclerosis associated with the slowed cognitive processing.
    Zhou F; Zhuang Y; Wu L; Zhang N; Zeng X; Gong H; Zee CS
    Clin Imaging; 2014; 38(5):605-10. PubMed ID: 24973078
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Pitteri M; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Mult Scler; 2017 May; 23(6):848-854. PubMed ID: 27527906
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background.
    Rito Y; Flores J; Fernández-Aguilar A; Escalante-Membrillo C; Barboza MA; Amezcua L; Corona T
    Acta Neurol Belg; 2018 Mar; 118(1):47-52. PubMed ID: 28975580
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS.
    Skorve E; Lundervold AJ; Torkildsen Ø; Myhr KM
    Mult Scler Relat Disord; 2020 Nov; 46():102577. PubMed ID: 33296975
    [TBL] [Abstract][Full Text] [Related]  

  • 80. 5 -Alpha-dihydroxyprogesterone may contribute to perceptual processing and attention of the cases with relapsing remitting multiple sclerosis.
    Ozcan E; Akduman RC; Eyupoglu S; Bingol A; Balci Ekmekci O; Hatipoglu E
    Neurol Res; 2024 Feb; 46(2):132-138. PubMed ID: 37733038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.